1. Home
  2. FIEE vs PCSA Comparison

FIEE vs PCSA Comparison

Compare FIEE & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FiEE Inc

FIEE

FiEE Inc

N/A

Current Price

$2.46

Market Cap

15.6M

Sector

Utilities

ML Signal

N/A

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$0.28

Market Cap

14.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FIEE
PCSA
Founded
N/A
2011
Country
United States
United States
Employees
43
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.6M
14.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
FIEE
PCSA
Price
$2.46
$0.28
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.00
AVG Volume (30 Days)
N/A
1.1M
Earning Date
N/A
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
N/A
$0.15
52 Week High
N/A
$1.50

Technical Indicators

Market Signals
Indicator
FIEE
PCSA
Relative Strength Index (RSI) 54.24 48.05
Support Level $1.65 $0.27
Resistance Level $2.59 $0.30
Average True Range (ATR) 0.20 0.02
MACD 0.05 0.00
Stochastic Oscillator 84.51 62.34

Price Performance

Historical Comparison
FIEE
PCSA

About FIEE FiEE Inc

FiEE Inc, formerly Minim Inc is a digital service provider focused on integrating artificial intelligence and data analytics into content creation and brand management. The company offers a range of services designed to support creators, artists, and businesses in developing, managing, and optimizing their digital presence across various platforms, including customized graphic and posts, short videos, and editorial calendars aligned with brand goals.

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Share on Social Networks: